Slide 1: Enabling the Nervous System to Repair Itself
Enabling the Nervous System to Repair Itself C O R P O R AT E P R E S E N TAT I O N June 23, 2022
Slide 2: Financial Disclosure Statement
Financial Disclosure Statement Not an offer or solicitation: This document is provided for general information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction. The contents of this document have not been approved or disappr
Slide 3: NervGen's Clinical Trials are Led by Experienced Drug Developers
NervGen’s Clinical Trials are Led by Experienced Drug Developers Paul Brennan Dr. Dan Mikol, MD, PhD President & CEO Chief Medical Officer • 30+years of biotech and pharma commercial and • 25+ years pharma experience and as practicing development experience neurologist conducting clinical research •
Slide 4: NVG-291: A Pipeline in a Product
NVG-291: A Pipeline in a Product STAGE OF DEVELOPMENT Phase 1b/2 Phase 1b/2 INDICATION Phase 1 Initiation Readout ESTIMATED COST MARKET OPPORTUNITY • ~6,000,000 patients in the US Alzheimer’s Q4 2022 2024 $20 M • US Market potential of over $300 billion Disease • Substantial pharma deal dynamics • ~
Slide 5: Revolutionizing the Treatment of Nervous System Damage
Revolutionizing the Treatment of Nervous System Damage Everyone KNOWS… Everyone BELIEVES… The nervous system is a The nervous system complex system that cannot repair itself controls thought, movement, senses, etc. 5
Slide 6: NVG-291 – First-in-Class Neuroreparative Drug
NVG-291 – First-in-Class Neuroreparative Drug Representative of Placebo Group Representative of NVG-291 Group (Back Legs and Tail Dragging) (Back Legs and Tail Active) Remarkable and robust repair across multiple models 6 Rink et al., 2018 SEVERE SPINAL CORD INJURY MODEL
Slide 7: NervGen's Technology Was Invented by Dr. Jerry Silver
NervGen’s Technology Was Invented by Dr. Jerry Silver Known in the Spinal Cord Injury Field as the “Oracle” Dr. Silver’s Spinal Cord Research • Discovered why the nervous system does not repair itself STRONG IP PORTFOLIO • Identified the surprising molecules responsible NervGen licensed the technolo
Slide 8: The Evolution of Our Proprietary Science
The Evolution of Our Proprietary Science Pre 1990 1990s 2009 2015 It was demonstrated Dr. Silver identified a class of Dr. Silver and collaborators from Dr. Silver's team then that glial scars form at the molecules called CSPGs, Harvard co-discovered that identified NVG-291, a drug site of injury to
Slide 9: NVG-291 Allows Neurons to Grow in the Scar
NVG-291 Allows Neurons to Grow in the Scar NVG-291 frees Neuron bound to neuron from CSPGs and unable CSPGs and allows to grow it to grow NVG-291, a 35 amino acid peptide, produced dramatic recovery in a spinal cord injury animal study: the results published in Nature1 are now cited in over 327 publ
Slide 10: The Body's Powerful Innate Repair Mechanisms
The Body’s Powerful Innate Repair Mechanisms Disrupted by CSPGs Repair Mechanisms: Injury Scar Formation Plasticity The creation of new neuronal connections and rewiring of existing ones Injury Brain Upregulation of CSPGs Axonal Regeneration The ability of a severed axon to reestablish connectivity
Slide 11: NVG-291 Takes the Brakes off Natural Repair Mechanisms
NVG-291 Takes the Brakes off Natural Repair Mechanisms Repair Mechanisms: Plasticity Injury Scar Formation The creation of new neuronal connections and rewiring of existing ones Injury Brain Upregulation of CSPGs Axonal Regeneration The ability of a severed axon to reestablish connectivity with othe
Slide 12: NVG-291 Broadly Restores Function
NVG-291 Broadly Restores Function NVG-291 Has Demonstrated Dramatic Repair in multiple animal models of neurological injury/disease, as documented in 15+ peer-reviewed papers ACUTE SPINAL PERIPHERAL MULTIPLE OPTIC CORD INJURY NERVE INJURY SCLEROSIS NEURITIS STROKE • Motor • Motor • Motor • Visual •
Slide 13: NVG-291: Potential to Treat All Types of Nervous System Damage
NVG-291: Potential to Treat All Types of Nervous System Damage TRAUMA DISEASE Acute Spinal Cord Injury Multiple Sclerosis Alzheimer’s Disease Chronic Spinal Cord Injury Stroke NVG-291 ALS Traumatic Brain Injury Frontotemporal Dementia Parkinson’s Disease NervGen Priorities 13
Slide 14: NVG-291 - Phase 1 Clinical Trial in Progress
NVG-291 - Phase 1 Clinical Trial in Progress Single Ascending Dose (SAD) – COMPLETED Multiple Ascending Dose (MAD) – IN PROGRESS • NVG-291 was well tolerated at a high dose • Subjects are dosed once a day for 14 days - 170% higher than the equivalent highest dose in preclinical • Currently conductin
Slide 15: Alzheimer's Disease: No FDA Approved Drug for Sustained Cognitive Improvement
Alzheimer’s Disease No FDA Approved Drug that Results in Sustained Improvement in Cognitive Function • Symptomatic treatments to improve cognition in Alzheimer's disease are unsatisfactory • A disease–modifying therapy approved in 2021 has questionable benefit in slowing cognitive decline • NervGen
Slide 16: NVG-291 – Improves Memory and Spatial Learning
NVG-291 – Improves Memory and Spatial Learning STROKE MODEL Significant improvement in cognitive function when Barnes Maze Test treated 24 hours - and even 7 days NVG-291 treatment beginning 7 days post stroke 16 Unpublished data provided by Dr. Agnes Lou, University of Cincinnati
Slide 17: NVG-291 Pathway to Treat Alzheimer's Disease
NVG-291 Pathway to Treat Alzheimer’s Disease CSPG ACCUMULATION IN AD PATIENT BRAINS1 Preclinical studies have demonstrated (CSPGs) Brevican/GAPDH that breaking down CSPGs 2.5 improves Alzheimer's symptoms2,3 * 2.0 1.5 Removing PTPσ improves cognitive function in Alzheimer’s models4 1.0 0.5 NVG-291’s
Slide 18: NVG-291 Safety/Efficacy Studies in Alzheimer's Disease Patients
NVG-291 Safety/Efficacy Studies in Alzheimer's Disease Patients 2022 2023 2024 • Multicenter, placebo controlled Alzheimer’s Phase 1b/2a • Efficacy analysis includes functional and structural imaging, cognitive assessments and ~80 patients, ~$20 million estimated cost fluid biomarkers World-class Ad
Slide 19: Spinal Cord Injury: No FDA Approved Drug that Improves Function
Spinal Cord Injury No FDA Approved Drug that Improves Function • NervGen’s goal is to improve motor, bladder/bowel/sexual and/or sensory function 19
Slide 20: NVG-291 – Dramatically Repairs Spinal Cord Injury
NVG-291 – Dramatically Repairs Spinal Cord Injury S E V E R E S P I N A L C O R D I N J U RY M O D E L Representative of Placebo Group Representative of NVG-291 Group Hind legs are immobile Significant motor recovery: consistent coordination, toe clearance, tail held high consistently 20 Rink, S. et
Slide 21: Spinal Cord Injury – NVG-291 Promotes Functional Recovery
Spinal Cord Injury – NVG-291 Promotes Functional Recovery BBB Scale = Standard measure of mobility 21 = Normal function 20 # NVG-291 500ug UNPRECEDENTED ≥14 = fine motor # (N=5) RESULTS movements # 15 # Extremely high ≤13 = Occasional response rate coordination 10 50% Placebo Almost complete (N=20)
Slide 22: NVG-291 Improves Bladder Function
NVG-291 Improves Bladder Function BLADDER DOSE RESPONSE 1.5 Void Frequency ** 100% of animals in the * two highest dose groups 1.0 had improved bladder Responders (2x SD of vehicle mean) control function NVG-291 treatment resulted 0.5 in a dose dependent improvement in bladder function 0.0 Vehicle 3
Slide 23: NVG-291 Safety/Efficacy Studies in Spinal Cord Injury Patients
NVG-291 Safety/Efficacy Studies in Spinal Cord Injury Patients 2022 2023 2024 • Single center, placebo controlled Spinal Cord Injury Phase 1b/2a • Efficacy analysis includes electrophysiology, clinical assessments of upper and lower ~16 patients per arm, minimum 32 patients extremity function ~$10 m
Slide 24: Multiple Sclerosis Repair: No FDA Approved Drug that Improves Function
Multiple Sclerosis Repair No FDA Approved Drug that Improves Function • MS is an autoimmune disease where the immune system attacks myelin in the central nervous system, and over time this results in increasing disability • Approved disease-modifying drugs modulate the immune system, which can reduc
Slide 25: NVG-291 Restores Motor Function in Multiple Sclerosis
NVG-291 Restores Motor Function in Multiple Sclerosis Representative of Placebo Group Representative of NVG-291 Group Score never improves from 3.5 Score improves to 0.5 in 20 days NVG-291 restored motor function in MS model1, even when administered after symptoms were fully developed 25 1Luo, F. et
Slide 26: NVG-291 Remyelinates in Multiple Sclerosis
NVG-291 Remyelinates in Multiple Sclerosis POSITIVE PLACEBO NVG-291 PRECLINICAL RESULTS1 Animals treated with NVG-291 had substantially greater remyelination 3 days compared to placebo treated animals after 21 days post-lesion Histological evidence showed that the desired types of cells were migrati
Slide 27: NVG-291 Safety/Efficacy Studies in Multiple Sclerosis Patients
NVG-291 Safety/Efficacy Studies in Multiple Sclerosis Patients 2022 2023 2024 • Multicenter, placebo controlled Multiple Sclerosis Phase 2 • Efficacy analysis includes clinical assessments, advanced structural imaging ~80 patients, ~$20 million estimated costs and fluid biomarkers World-class Adviso
Slide 28: Share and Capital Structure
Share and Capital Structure Exchange/Market: Ticker TSX: NGEN.V OTCQX: NGENF Recent Share Price CA $1.65 US $1.28 (June 21, 2022) Shares Outstanding 47.9 million 63.7 million Fully Diluted (~7.1 million options, ~8.7 million warrants) Insider Ownership 10% ~Cash & Cash Equivalents CA $12.8 million U
Slide 29: Upcoming Value Drivers
Upcoming Value Drivers PHASE INITIATION READOUT ADVANCED Alzheimer’s Disease 1b/2a Q4 2022 2024 CLINICAL TRIAL PROGRAM Spinal Cord Injury 1b/2a Q4 2022 2023 Multiple Sclerosis 2 Q1 2023 2024 • Phase 1 study topline MAD data (2022) • Preclinical study results in stroke, chronic spinal cord injury and
Slide 30: Investment Highlights
Investment Highlights NVG-291 has the potential to redefine treatment paradigms for neurological disorders Improvement demonstrated across 6 different animal models in fine and gross motor control, sensory function, autonomic functions, visual acuity, memory & learning, in many cases unprecedented P
Slide 31: Enabling the Nervous System to Repair Itself
Enabling the Nervous System to Repair Itself www.nervgen.com @NervgenP NervGen Pharma Corp.